Imaging serotonergic transmission with [11C]DASB-PET in depressed and non-depressed patients infected with HIV

NeuroImage

Volumn 49, Issue 3, 2010, Pages 2588-2595

  Hammoud, Dima A ^a   Endres, Christopher J ^b   Hammond, Edward ^b   Uzuner, Ovsev ^b   Brown, Amanda ^b   Nath, Avindra ^b   Kaplin, Adam I ^b   Pomper, Martin G ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

5 HTT; Molecular imaging; NeuroAIDS; Positron emission tomography; Serotonin

Indexed keywords

ANTIRETROVIRUS AGENT; CARBON 11; SEROTONIN; SEROTONIN TRANSPORTER;

ADULT; ARTICLE; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULA; MESENCEPHALON; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PONS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; SEROTONINERGIC TRANSMISSION; SYNAPSE; THALAMUS;

ADULT; BENZYLAMINES; CARBON RADIOISOTOPES; DEPRESSION; HIV INFECTIONS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; POSITRON-EMISSION TOMOGRAPHY; PROMOTER REGIONS, GENETIC; RADIOPHARMACEUTICALS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; YOUNG ADULT;

EID: 71949118019     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2009.10.037     Document Type: Article

References (83)

1. Bell C.J., Hood S.D., and Nutt D.J. Acute tryptophan depletion. Part II: clinical effects and implications. Aust. N. Z. J. Psychiatry 39 (2005) 565-574
2. Bhagwagar Z., Murthy N., Selvaraj S., Hinz R., Taylor M., Fancy S., Grasby P., and Cowen P. 5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB. Am. J. Psychiatry 164 (2007) 1858-1865
3. Brown A.K., George D.T., Fujita M., Liow J.S., Ichise M., Hibbeln J., Ghose S., Sangare J., Hommer D., and Innis R.B. PET [11C]DASB imaging of serotonin transporters in patients with alcoholism. Alcohol. Clin. Exp. Res. 31 (2007) 28-32
4. Buckner C.M., Luers A.J., Calderon T.M., Eugenin E.A., and Berman J.W. Neuroimmunity and the blood-brain barrier: molecular regulation of leukocyte transmigration and viral entry into the nervous system with a focus on neuroAIDS. J. Neuroimmune. Pharmacol. 1 (2006) 160-181
5. Caballero J., and Nahata M.C. Use of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIV. Ann. Pharmacother. 39 (2005) 141-145
6. Cannon D.M., Ichise M., Fromm S.J., Nugent A.C., Rollis D., Gandhi S.K., Klaver J.M., Charney D.S., Manji H.K., and Drevets W.C. Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol. Psychiatry 60 (2006) 207-217
7. Cannon D.M., Ichise M., Rollis D., Klaver J.M., Gandhi S.K., Charney D.S., Manji H.K., and Drevets W.C. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol. Psychiatry 62 (2007) 870-877
8. Cao M.Q., Hu S.Y., Zhang C.H., and Xia D.S. Study on the interrelationship between 5-HTTLPR/G-protein beta3 subunit (C825T) polymorphisms and depressive disorder. Psychiatr. Genet. 17 (2007) 233-238
9. Catz S.L., Kelly J.A., Bogart L.M., Benotsch E.G., and McAuliffe T.L. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 19 (2000) 124-133
10. Cervilla J.A., Rivera M., Molina E., Torres-Gonzalez F., Bellon J.A., Moreno B., de Dios Luna J., Lorente J.A., de Diego-Otero Y., King M., Nazareth I., and Gutierrez B. The 5-HTTLPR s/s genotype at the serotonin transporter gene (SLC6A4) increases the risk for depression in a large cohort of primary care attendees: the PREDICT-gene study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141 (2006) 912-917
11. Ciesla J.A., and Roberts J.E. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am. J. Psychiatry 158 (2001) 725-730
12. Cruess D.G., Evans D.L., Repetto M.J., Gettes D., Douglas S.D., and Petitto J.M. Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. Biol. Psychiatry 54 (2003) 307-316
13. Derogatis L. The Symptom Checklist-90-revised (1992), NCS Assessments, Minneapolis, MN
14. Derogatis L. SCL-90-R, Administration, scoring, and Procedures Manual for the R(evised) Version (1997), Johns Hopkins University School of Medicine, Baltimore, MD
15. Dorado P., Penas-Lledo E.M., Gonzalez A.P., Caceres M.C., Cobaleda J., and Llerena A. Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele. Fundam. Clin. Pharmacol. 21 (2007) 451-453
16. Dube B., Benton T., Cruess D.G., and Evans D.L. Neuropsychiatric manifestations of HIV infection and AIDS. J. Psychiatry Neurosci. 30 (2005) 237-246
17. Dursun S.M., and Reveley M.A. Serotonin hypothesis of psychiatric disorders during HIV infection. Med. Hypotheses 44 (1995) 263-267
18. Elliott A.J., Russo J., Bergam K., Claypoole K., Uldall K.K., and Roy-Byrne P.P. Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. J. Clin. Psychiatry 60 (1999) 226-231
19. Elliott A.J., Uldall K.K., Bergam K., Russo J., Claypoole K., and Roy-Byrne P.P. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am. J. Psychiatry 155 (1998) 367-372
20. Endres C.J., Slifstein M., Frankle G., Talbot P.S., and M L. Simultaneous modeling of multiple brain time-activity curves with parameter coupling: applications using reference tissue models. XXIst International Symposium on Cerebral Blood Flow, Metabolism, and Function. Calgary, Canada, Calgary, Canada (2003) S676M
21. Farr S.A., Banks W.A., Uezu K., Freed E.O., Kumar V.B., and Morley J.E. Mechanisms of HIV type 1-induced cognitive impairment: evidence for hippocampal cholinergic involvement with overstimulation of the VIPergic system by the viral coat protein core. AIDS Res. Hum. Retroviruses 18 (2002) 1189-1195
22. Fernandes S.P., Edwards T.M., Ng K.T., and Robinson S.R. HIV-1 protein gp120 rapidly impairs memory in chicks by interrupting the glutamate-glutamine cycle. Neurobiol. Learn. Mem. 87 (2007) 1-8
23. Frankle W.G., Slifstein M., Gunn R.N., Huang Y., Hwang D.R., Darr E.A., Narendran R., Abi-Dargham A., and Laruelle M. Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: reproducibility and comparison of methods. J. Nucl. Med. 47 (2006) 815-826
24. Gallinat J., Muller D.J., Bierbrauer J., Rommelspacher H., Juckel G., and Wernicke C. Functional cortical effects of novel allelic variants of the serotonin transporter gene-linked polymorphic region (5-HTTLPR) in humans. Pharmacopsychiatry 40 (2007) 191-195
25. Ginovart N., Wilson A.A., Meyer J.H., Hussey D., and Houle S. Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: modeling strategies. J. Cereb. Blood Flow. Metab. 21 (2001) 1342-1353
26. Ginovart N., Wilson A.A., Meyer J.H., Hussey D., and Houle S. [11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. Synapse 47 (2003) 123-133
27. Gonda X., Rihmer Z., Juhasz G., Zsombok T., and Bagdy G. High anxiety and migraine are associated with the s allele of the 5HTTLPR gene polymorphism. Psychiatry Res. 149 (2007) 261-266
28. Hayden E.P., Dougherty L.R., Maloney B., Olino T.M., Sheikh H., Durbin C.E., Nurnberger Jr. J.I., Lahiri D.K., and Klein D.N. Early-emerging cognitive vulnerability to depression and the serotonin transporter promoter region polymorphism. J. Affect. Disord. 107 (2008) 227-230
29. Holi M.M., Sammallahti P.R., and Aalberg V.A. A Finnish validation study of the SCL-90. Acta Psychiatr. Scand. 97 (1998) 42-46
30. Hood S.D., Bell C.J., and Nutt D.J. Acute tryptophan depletion. Part I: rationale and methodology. Aust. N. Z. J. Psychiatry 39 (2005) 558-564
31. Horberg M.A., Silverberg M.J., Hurley L.B., Towner W.J., Klein D.B., Bersoff-Matcha S., Weinberg W.G., Antoniskis D., Mogyoros M., Dodge W.T., Dobrinich R., Quesenberry C.P., and Kovach D.A. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J. Acquir. Immune. Defic. Syndr. (2007)
32. Ichise M., Liow J.S., Lu J.Q., Takano A., Model K., Toyama H., Suhara T., Suzuki K., Innis R.B., and Carson R.E. Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J. Cereb. Blood Flow. Metab. 23 (2003) 1096-1112
33. Jenuwein M., Scheller C., Neuen-Jacob E., Sopper S., Tatschner T., ter Meulen V., Riederer P., and Koutsilieri E. Dopamine deficits and regulation of the cAMP second messenger system in brains of simian immunodeficiency virus-infected rhesus monkeys. J. Neurovirol. 10 (2004) 163-170
34. Kalichman S.C., Kelly J.A., and Rompa D. Continued high-risk sex among HIV seropositive gay and bisexual men seeking HIV prevention services. Health Psychol. 16 (1997) 369-373
35. Kaul M., and Lipton S.A. Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr. HIV Res. 4 (2006) 307-318
36. Kim J.S., Ichise M., Sangare J., and Innis R.B. PET imaging of serotonin transporters with [11C]DASB: test-retest reproducibility using a multilinear reference tissue parametric imaging method. J. Nucl. Med. 47 (2006) 208-214
37. Kish S.J., Furukawa Y., Chang L.J., Tong J., Ginovart N., Wilson A., Houle S., and Meyer J.H. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region?. Nucl. Med. Biol. 32 (2005) 123-128
38. Knekt P., Lindfors O., Harkanen T., Valikoski M., Virtala E., Laaksonen M.A., Marttunen M., Kaipainen M., and Renlund C. Randomized trial on the effectiveness of long-and short-term psychodynamic psychotherapy and solution-focused therapy on psychiatric symptoms during a 3-year follow-up. Psychol. Med. 38 (2008) 689-703
39. Kopnisky K.L., Stoff D.M., and Rausch D.M. Workshop report: the effects of psychological variables on the progression of HIV-1 disease. Brain Behav. Immun. 18 (2004) 246-261
40. Koutsilieri E., Sopper S., Scheller C., ter Meulen V., and Riederer P. Parkinsonism in HIV dementia. J. Neural. Transm. 109 (2002) 767-775
41. Lammertsma A.A., and Hume S.P. Simplified reference tissue model for PET receptor studies. Neuroimage 4 (1996) 153-158
42. Lee H.J., Lee M.S., Kang R.H., Kim H., Kim S.D., Kee B.S., Kim Y.H., Kim Y.K., Kim J.B., Yeon B.K., Oh K.S., Oh B.H., Yoon J.S., Lee C., Jung H.Y., Chee I.S., and Paik I.H. Influence of the serotonin transporter promoter gene polymorphism on susceptibility to posttraumatic stress disorder. Depress Anxiety 21 (2005) 135-139
43. Lichtenberg P., Shapira B., Gillon D., Kindler S., Cooper T.B., Newman M.E., and Lerer B. Hormone responses to fenfluramine and placebo challenge in endogenous depression. Psychiatry Res. 43 (1992) 137-146
44. Lundquist P., Wilking H., Hoglund A.U., Sandell J., Bergstrom M., Hartvig P., and Langstrom B. Potential of [11C]DASB for measuring endogenous serotonin with PET: binding studies. Nucl. Med. Biol. 32 (2005) 129-136
45. McArthur J.C., Haughey N., Gartner S., Conant K., Pardo C., Nath A., and Sacktor N. Human immunodeficiency virus-associated dementia: an evolving disease. J. Neurovirol. 9 (2003) 205-221
46. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., and Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 352 (1998) 1433-1437
47. McCann U.D., Szabo Z., Seckin E., Rosenblatt P., Mathews W.B., Ravert H.T., Dannals R.F., and Ricaurte G.A. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 30 (2005) 1741-1750
48. Meyer J.H. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J. Psychiatry Neurosci. 32 (2007) 86-102
49. Meyer J.H., Houle S., Sagrati S., Carella A., Hussey D.F., Ginovart N., Goulding V., Kennedy J., and Wilson A.A. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch. Gen. Psychiatry 61 (2004) 1271-1279
50. Meyer J.H., Kapur S., Eisfeld B., Brown G.M., Houle S., DaSilva J., Wilson A.A., Rafi-Tari S., Mayberg H.S., and Kennedy S.H. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am. J. Psychiatry 158 (2001) 78-85
51. Must A., Juhasz A., Rimanoczy A., Szabo Z., Keri S., and Janka Z. Major depressive disorder, serotonin transporter, and personality traits: why patients use suboptimal decision-making strategies?. J. Affect. Disord. 103 (2007) 273-276
52. Nosheny R.L., Bachis A., Aden S.A., De Bernardi M.A., and Mocchetti I. Intrastriatal administration of human immunodeficiency virus-1 glycoprotein 120 reduces glial cell-line derived neurotrophic factor levels and causes apoptosis in the substantia nigra. J. Neurobiol. 66 (2006) 1311-1321
53. Parsey R.V., Hastings R.S., Oquendo M.A., Hu X., Goldman D., Huang Y.Y., Simpson N., Arcement J., Huang Y., Ogden R.T., Van Heertum R.L., Arango V., and Mann J.J. Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am. J. Psychiatry 163 (2006) 48-51
54. Parsey R.V., Kent J.M., Oquendo M.A., Richards M.C., Pratap M., Cooper T.B., Arango V., and Mann J.J. Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. Biol. Psychiatry 59 (2006) 821-828
55. Pezawas L., Meyer-Lindenberg A., Drabant E.M., Verchinski B.A., Munoz K.E., Kolachana B.S., Egan M.F., Mattay V.S., Hariri A.R., and Weinberger D.R. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat. Neurosci. 8 (2005) 828-834
56. Praschak-Rieder N., Kennedy J., Wilson A.A., Hussey D., Boovariwala A., Willeit M., Ginovart N., Tharmalingam S., Masellis M., Houle S., and Meyer J.H. Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)C] DASB positron emission tomography study. Biol. Psychiatry 62 (2007) 327-331
57. Praschak-Rieder N., Wilson A.A., Hussey D., Carella A., Wei C., Ginovart N., Schwarz M.J., Zach J., Houle S., and Meyer J.H. Effects of tryptophan depletion on the serotonin transporter in healthy humans. Biol. Psychiatry 58 (2005) 825-830
58. Rabkin J.G., Wagner G.J., and Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am. J. Psychiatry 156 (1999) 101-107
59. Reimold M., Smolka M.N., Schumann G., Zimmer A., Wrase J., Mann K., Hu X.Z., Goldman D., Reischl G., Solbach C., Machulla H.J., Bares R., and Heinz A. Midbrain serotonin transporter binding potential measured with [11C]DASB is affected by serotonin transporter genotype. J. Neural. Transm. 114 (2007) 635-639
60. Reneman L., Lavalaye J., Schmand B., de Wolff F.A., van den Brink W., den Heeten G.J., and Booij J. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings. Arch. Gen. Psychiatry 58 (2001) 901-906
61. Repetto M.J., Evans D.L., Cruess D.G., Gettes D.R., Douglas S.D., and Petitto J.M. Neuropsychopharmacologic treatment of depression and other neuropsychiatric disorders in HIV-infected individuals. CNS Spectr. 8 (2003) 59-63
62. Safren S.A., Otto M.W., Worth J.L., Salomon E., Johnson W., Mayer K., and Boswell S. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav. Res. Ther. 39 (2001) 1151-1162
63. Schmitz N., Kruse J., and Tress W. Improving screening for mental disorders in the primary care setting by combining the GHQ-12 and SCL-90-R subscales. Compr. Psychiatry 42 (2001) 166-173
64. Schwartz J.A., and McDaniel J.S. Double-blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: a pilot study. Depress Anxiety 9 (1999) 70-74
65. Skydsbjerg M., Lunn S., and Hutchings B. Psychosocial aspects of human immunodeficiency virus (HIV) infection in a pre-HAART sample. Scand. J. Psychol. 42 (2001) 327-333
66. Spitzer R.L., Williams J.B., Gibbon M., and First M.B. The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description. Arch. Gen. Psychiatry 49 (1992) 624-629
67. Starace F., Ammassari A., Trotta M.P., Murri R., De Longis P., Izzo C., Scalzini A., d'Arminio Monforte A., Wu A.W., and Antinori A. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 31 Suppl. 3 (2002) S136-S139
68. Stout J.C., Ellis R.J., Jernigan T.L., Archibald S.L., Abramson I., Wolfson T., McCutchan J.A., Wallace M.R., Atkinson J.H., and Grant I. Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal volumetric magnetic resonance imaging study. HIV Neurobehavioral Research Center Group. Arch. Neurol. 55 (1998) 161-168
69. Szabo Z., McCann U.D., Wilson A.A., Scheffel U., Owonikoko T., Mathews W.B., Ravert H.T., Hilton J., Dannals R.F., and Ricaurte G.A. Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J. Nucl. Med. 43 (2002) 678-692
70. Takano A., Arakawa R., Hayashi M., Takahashi H., Ito H., and Suhara T. Relationship between neuroticism personality trait and serotonin transporter binding. Biol. Psychiatry 62 (2007) 588-592
71. Takano A., Suhara T., Ichimiya T., Yasuno F., and Suzuki K. Time course of in vivo 5-HTT transporter occupancy by fluvoxamine. J. Clin. Psychopharmacol. 26 (2006) 188-191
72. Takano A., Suzuki K., Kosaka J., Ota M., Nozaki S., Ikoma Y., Tanada S., and Suhara T. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl) 185 (2006) 395-399
73. Talbot P.S., Frankle W.G., Hwang D.R., Huang Y., Suckow R.F., Slifstein M., Abi-Dargham A., and Laruelle M. Effects of reduced endogenous 5-HT on the in vivo binding of the serotonin transporter radioligand 11C-DASB in healthy humans. Synapse 55 (2005) 164-175
74. Trepanier L.L., Rourke S.B., Bayoumi A.M., Halman M.H., Krzyzanowski S., and Power C. The impact of neuropsychological impairment and depression on health-related quality of life in HIV-infection. J. Clin. Exp. Neuropsychol. 27 (2005) 1-15
75. van Velden F.H., Kloet R.W., van Berckel B.N., Buijs F.L., Luurtsema G., Lammertsma A.A., and Boellaard R. HRRT versus HR+ human brain PET studies: an Interscanner Test-Retest study. J. Nucl. Med. 50 (2009) 693-702
76. Varnas K., Halldin C., and Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum. Brain Mapp. 22 (2004) 246-260
77. Voineskos A.N., Wilson A.A., Boovariwala A., Sagrati S., Houle S., Rusjan P., Sokolov S., Spencer E.P., Ginovart N., and Meyer J.H. Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. Psychopharmacology (Berl) 193 (2007) 539-545
78. Wang G.J., Chang L., Volkow N.D., Telang F., Logan J., Ernst T., and Fowler J.S. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127 (2004) 2452-2458
79. Wang Z., Pekarskaya O., Bencheikh M., Chao W., Gelbard H.A., Ghorpade A., Rothstein J.D., and Volsky D.J. Reduced expression of glutamate transporter EAAT2 and impaired glutamate transport in human primary astrocytes exposed to HIV-1 or gp120. Virology 312 (2003) 60-73
80. Wienhard K., Schmand M., Casey M.E., Baker K., Bao J., Eriksson L., Jones W.F., Knoess C., Lenox M., Lercher M., Luk P., Michel C., Reed J.H., Richerzhagen N., Treffert J., Vollmar S., Young J.W., Heiss W.D., and Nutt R. The ECAT HRRT: performance and first clinical application of the new high resolution research tomograph. Nuclear Science, IEEE Transactions on 49 (2002) 104-110
81. Williams J.B., Gibbon M., First M.B., Spitzer R.L., Davies M., Borus J., Howes M.J., Kane J., Pope Jr. H.G., Rounsaville B., et al. The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability. Arch. Gen. Psychiatry 49 (1992) 630-636
82. Wilson A.A., Ginovart N., Hussey D., Meyer J., and Houle S. In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl. Med. Biol. 29 (2002) 509-515
83. Wu Y., and Carson R.E. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J. Cereb. Blood Flow. Metab. 22 (2002) 1440-1452